Bioengineering and Imaging Merge at NIH

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) will become fully functional by Oct. 31, burying a two-decade struggle between powerful foes. That fight reached crisis point on the last working day of 2000, when former President Bill Clinton was faced with deciding whether to sign a federal law sanctioning the 19th institute at the National Institutes of Health. To approve NIBIB, he would have to override the opposition of numerous scientific groups and of his Health and

Written bySteve Bunk
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

More than 40 scientific organizations and 170 cosponsors in the House of Representatives were in favor of the bill. Yet it looked ready to expire in the Senate during the waning days of the 106th Congress, until Majority Leader Trent Lott (R-Miss.) unexpectedly ushered it through a voice vote at the close of the Dec. 15 session. A week later, Clinton was sent a letter hastily organized by the American Psychological Society (APS) and cosigned by 22 other science and public health groups, urging a veto.

Resistance to NIBIB stemmed from its unusual focus on technology rather than on a disease or organ system. Imaging and bioengineering are conducted in virtually all the institutes, raising concerns that NIBIB would apply much of the funding available for such research to projects unrelated to specific disorders.

Since the early 1980s, several attempts had been made to reconfigure NIH laboratories or form centers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies